Andrii Domanskyi
Institute of Biotechnology,
HiLIFE,
Institute of Biotechnology, HiLIFE
University of Helsinki
Dr. Andrii Domanskyi is a Principal Investigator and a research group leader at the Institute of Biotechnology, University of Helsinki. He received his undergraduate with honors degree from Moscow Institute of Physics and Technology, and a PhD from the University of Helsinki, Finland.
Dr. Domanskyi main research interest is finding novel neuroprotective strategies combining neurotrophic factors, drugs and non-coding RNAs targeting specific pro-survival cellular pathways. His interest in molecular neuroscience started during post-doctoral work in Prof. Günther Schütz’s lab at the German Cancer Research Institute (DKFZ) in Heidelberg, where he moved after receiving PhD from the Faculty of Medicine, University of Helsinki. As a post-doctoral scientist at DKFZ Heidelberg, he used in vivo tissue-specific inducible transgenic mouse models to study pro-survival pathways in adult dopaminergic neurons.
In 2014 Dr. Domanskyi returned to Finland as a senior post-doctoral scientist in a Business Finland-funded 3iRegeneration project to study neural stem cells, transcription factors, and neurotrophic factors in models of Parkinson’s disease. During his training at Optogenetics and Transgenic Technology Core facility at the National Institute on Drug Abuse (NIDA), USA, he gained expertise in modern tools for somatic transgenesis and in vivo gene editing (CRISPR-Cas9), and development of reporter systems for drug discovery.
In 2015 Dr. Domanskyi received the Academy of Finland Research Fellowship and established a research group at the Institute of Biotechnology, University of Helsinki.
Biochemical characterization of androgen receptor-interacting protein 4.
The Biochemical journal Feb, 2006 | Pubmed ID: 16212558
Expression and localization of androgen receptor-interacting protein-4 in the testis.
American journal of physiology. Endocrinology and metabolism Feb, 2007 | Pubmed ID: 17003240
An adenosine triphosphatase of the sucrose nonfermenting 2 family, androgen receptor-interacting protein 4, is essential for mouse embryonic development and cell proliferation.
Molecular endocrinology (Baltimore, Md.) Jun, 2007 | Pubmed ID: 17374848
Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy.
Human gene therapy Aug, 2015 | Pubmed ID: 26176331
Update of neurotrophic factors in neurobiology of addiction and future directions.
Neurobiology of disease 01, 2017 | Pubmed ID: 27189755
AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models.
Genes Feb, 2017 | Pubmed ID: 28208742
Genetic mutations linked to Parkinson's disease differentially control nucleolar activity in pre-symptomatic mouse models.
Disease models & mechanisms 05, 2017 | Pubmed ID: 28360124
Dicer and microRNAs protect adult dopamine neurons.
Cell death & disease 05, 2017 | Pubmed ID: 28542144
Pancreatic β-cell protection from inflammatory stress by the endoplasmic reticulum proteins thrombospondin 1 and mesencephalic astrocyte-derived neutrotrophic factor (MANF).
The Journal of biological chemistry 09, 2017 | Pubmed ID: 28698383
MANF Promotes Differentiation and Migration of Neural Progenitor Cells with Potential Neural Regenerative Effects in Stroke.
Molecular therapy : the journal of the American Society of Gene Therapy 01, 2018 | Pubmed ID: 29050872
MANF Is Essential for Neurite Extension and Neuronal Migration in the Developing Cortex.
eNeuro Sep-Oct, 2017 | Pubmed ID: 29082311
Can we treat neurodegenerative diseases by preventing an age-related decline in microRNA expression?
Neural regeneration research Oct, 2017 | Pubmed ID: 29171418
Pre-α-pro-GDNF and Pre-β-pro-GDNF Isoforms Are Neuroprotective in the 6-hydroxydopamine Rat Model of Parkinson's Disease.
Frontiers in neurology , 2018 | Pubmed ID: 29973907
Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease.
Journal of neuroscience research 03, 2019 | Pubmed ID: 30548446
Neuron-Specific Genome Modification in the Adult Rat Brain Using CRISPR-Cas9 Transgenic Rats.
Neuron 04, 2019 | Pubmed ID: 30792150
Effects of Neurotrophic Factors in Glial Cells in the Central Nervous System: Expression and Properties in Neurodegeneration and Injury.
Frontiers in physiology , 2019 | Pubmed ID: 31105589
Engineered antibody-functionalized porous silicon nanoparticles for therapeutic targeting of pro-survival pathway in endogenous neuroblasts after stroke.
Biomaterials 01, 2020 | Pubmed ID: 31670035
Interplay between MicroRNAs and Oxidative Stress in Neurodegenerative Diseases.
International journal of molecular sciences Nov, 2019 | Pubmed ID: 31801298
Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.
Movement disorders : official journal of the Movement Disorder Society 02, 2020 | Pubmed ID: 31840869
Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models.
Current protocols in neuroscience Mar, 2020 | Pubmed ID: 32049438
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved